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Abstract
Transient elastography (TE) is a new non-invasive tool 
for assessing liver stiffness, which is correlated with 
the histologic stage of liver fibrosis. Many studies have 
reported a good accuracy of TE in predicting significant 
fibrosis and an optimal accuracy in predicting cirrhosis. 
Furthermore, the potential role of TE in screening the 
general population has also been proven. TE thus helps 
physicians to decide treatment strategies, predict prog-
nosis, and monitor disease progression in patients with 
chronic liver disease and to screen the general popula-
tion to identify high risk patients with potential liver 
disease. However, most data on the clinical roles of TE 
have been gathered in European patients with chronic 
hepatitis C (CHC), because TE was first developed in 
France. Accordingly, much data on the usefulness of 
TE in patients with CHC has accumulated. Recently, 
however, vigorous efforts have been made to apply TE 
to patients with chronic hepatitis B (CHB), and TE has 
also proved to have acceptable accuracy in diagnos-
ing liver fibrosis and cirrhosis in these patients. Thus, 
we focused on TE in the Asian population with CHB in 
comparison with the European population with CHC and 
found that the diagnostic performance and cutoff values 
were different between the 2 populations possibly as a 
result of several different confounders between Asian 
and European populations (the etiology of chronic liver 
disease, histologic features, major fluctuation in alanine 
aminotransferase levels, and the prevalence of high 
body mass index and metabolic syndrome). Therefore, 
further studies tailored to the Asian population with CHB 
should be performed before the widespread application 
of TE in Asian populations with CHB.
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INTRODUCTION
Transient elastography (TE) using FibroScan® (EchoSens, 
Paris, France) is a newly introduced non-invasive tool, 
that generates an elastic wave using a vibrator applied 
to the thoracic wall at the level of  the right lobe of  the 
liver and measures the propagation velocity of  the wave, 
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which is directly associated with liver stiffness (LS)[1]. To 
date, the clinical utility of  TE has been widely reviewed, 
and it is regarded as having considerable accuracy for 
predicting liver cirrhosis in patients with chronic liver 
disease (CLD) of  diverse etiologies[2-5]. TE is quick, 
highly reproducible, and completely harmless to patients. 
In addition, it can be learned and performed easily after 
a short training period (by nurses or technicians) without 
consuming the time of  clinicians. For these reasons, TE 
has become popular in clinical practice as a tool for aid-
ing in the diagnosis and follow-up of  liver disease.
Because TE was first developed in France, most studies 
on its benefits have been explored in European countries 
where chronic hepatitis C (CHC) is prevalent. Accord-
ingly, extensive data on the clinical roles of  TE in assessing 
liver fibrosis in patients with CHC have been gathered. 
Recently, several meta-analysis studies reported that TE is 
a reliable non-invasive tool to detect advanced liver fibro-
sis and liver cirrhosis[6-8]. However, most studies included 
in the meta-analysis investigated European populations 
with CHC. Data from Europe cannot be extrapolated to 
the Asian population, as subsequent trials of  TE in Asian 
countries where hepatitis B virus (HBV) infection is more 
prevalent than hepatitis C virus (HCV), displayed divergent 
results. In this Topic Highlight, we will focus on TE in the 
Asian population with chronic hepatitis B (CHB).
METHODOLOGICAL CONSIDERATION OF 
TE IN THE ASIAN POPULATION 
LS values are defined as the median of  10 valid measure-
ments and at least 60% of  TE shots should be success-
ful for each examination according to the manufacturer’s 
recommendations. Accordingly, to date, only the results 
of  TE examinations satisfying the above criteria have 
been considered as reliable and have been included for 
the analysis in reported studies. 
Another important parameter for confirming the 
validity of  LS values is the interquartile range (IQR), 
which is defined as the values between which 50% of  
observations fall. The lower boundary is the 25th per-
centile (lower quartile), the upper boundary is the 75th 
percentile (upper quartile). Generally, the IQR/median 
LS value ratio (IQR/M) should not exceed 30% if  the 
reliability of  LS values is to be preserved. However, 
recently, Lucidarme et al[9] proposed new criteria for reli-
able LS values, using the IQR/M based on the data from 
more than 250 French patients with CHC. They found, 
in a multivariate analysis, the fibrosis stage (F0-2 vs F3-4) 
and IQR/M were significantly associated with signifi-
cant discordances between TE and liver biopsy (LB), 
with an optimal discriminant cutoff  value of  0.21. They 
thus concluded that the IQR/M can overestimate liver 
fibrosis using TE, irrespective of  success rate, when the 
significance discordance was defined as a discordance 
of  at least 2 stages of  fibrosis between LS values by TE 
examination and the METAVIR scoring system. From 
these results, they suggested a novel algorithm for clini-
cal practice as first-line assessment of  liver fibrosis in 
patients with CHC (Figure 1).
Because the IQR/M was confirmed in only one Euro-
pean study with CHC showing relatively high body mass 
index (BMI) (25 ± 4.1 kg/m2), its application to the Asian 
population with CHB (who generally show a lower BMI) 
is difficult and requires further validation. Although the 
data are preliminary, we have attempted to validate the 
IQR/M for our cohort of  156 patients with CHB (mean 
age 38.8 years, male 75.0%, mean BMI 23.2 kg/m2) who 
underwent LB and TE prior to starting antiviral treatment. 
In this study, we selected the cutoff  LS values of  Marcellin 
et al[10] (7.2 kPa for ≥ F2, 8.1 kPa ≥ F3, and 11.0 kPa for 
F4) as the reference values between 2 external studies that 
investigated the performance of  TE and then set up the 
optimal cutoff  LS values for each fibrosis stage in patients 
with CHB[10,11]. We identified 28 (18.0%) patients showing 
significant discordance between TE and LB. However, the 
IQR/M was not significantly different between patients 
with discordance and those with non-discordance (0.125 
± 0.083 vs 0.129 ± 0.079, P = 0.831), and the success rate 
also failed to show a significant difference. 
Interestingly, the mean IQR/M of  our study popula-
tion was greatly reduced compared to that of  subjects in 
Lucidarme et al[9] (0.30 in patients with discordance and 
0.22 in those with non-discordance) and the proportion 
of  patients with an IQR/M > 0.03 (n = 7, 4.5%) was very 
small. The reasons are not clear why the IQR/M in our 
study was reduced in comparison with that in the previ-
ous study, and was not selected as a discriminant factor to 
predict discordance. However, we think that the optimal 
cutoff  value of  the IQR/M will be lower than that from 
patients with CHC even if  the IQR/M can be validated 
in the future for the Asian population with CHB, or that 
the IQR/M is not a predictor of  discordance in the Asian 
population with CHB due to other potential confounders 
that overwhelm the influence of  the IQR/M, such as the 
inhomogeneous histological features of  CHB which often 
LSM
IQR/M 0.21-0.50IQR/M < 0.21 IQR/M ≥ 0.50
LSM < 9.5 kPa LSM ≥ 9.5 kPa
VALIDATED LSM Repeat LSM
IQR/M < 0.21 IQR/M ≥ 0.21
Liver biopsyBiomarkers
Figure 1  Suggested algorithm for clinical practice as first-line assessment 
of hepatic fibrosis in patients with chronic hepatitis C. IQR/M: Interquartile 
range/median liver stiffness value ratio; LSM: Liver stiffness measurement.
Kim SU et al . Transient elastography in chronic hepatitis B
5174 November 7, 2010|Volume 16|Issue 41|WJG|www.wjgnet.com
makes liver texture inherently macronodular. This would 
result in LS values that vary depending on the area of  the 
liver and necroinflammatory activity, which has been dem-
onstrated to raise LS values. Therefore, the validation of  
the IQR/M in the Asian population with CHB requires 
further studies using increased sample sizes to allow suf-
ficient cases with a spectrum of  IQR/M values.
Several issues still remain to be resolved regarding the 
Asian population with CHB: How many valid measure-
ments do we need to maintain the performance of  TE[12]? 
What is the optimal success rate of  the TE measurement 
to accurately exclude unreliable LS values? Can the IQR/
M alone be applied to increase the performance of  TE 
without a sufficient number of  valid measurements and 
an adequate success rate?
WHAT ARE THE NORMAL LS VALUES 
FOR THE ASIAN POPULATION
Before discussing data on TE in the Asian population 
with CHB, it is important to first confirm that TE can 
reliably identify patients with CLD from the normal 
population. If  TE cannot, the clinical meaning of  fur-
ther analysis on the performance of  TE in grading the 
severity of  CLD would be significantly lessened. Despite 
the importance of  this, to date, most studies on TE have 
focused on patients with CLD. 
The concept of  “what are normal LS values assessed 
by TE?” is a critical issue that should be addressed to de-
termine whether TE can be used for screening the gen-
eral population and for subsequent selection of  high-risk 
patients who require periodic follow-up and adequate 
treatment measures. Indeed, concerns regarding normal 
LS values are increasing, and several studies (including 2 
Asian studies) have proposed normal LS values despite 
variations in study design[13-19]. 
In a study by Corpechot et al[15], the authors found 
that the normal LS values in the healthy population were 
significantly higher in men than in women and that the 
median LS value was 4.8 kPa (range, 2.5-6.9 kPa). Roulot 
et al[13] examined a large cohort of  429 apparently healthy 
subjects to establish normal LS values [5.81 ± 1.54 kPa 
(range, 3.8-8.0 kPa) in men vs 5.23 ± 1.59 kPa (range, 3.3- 
7.8 kPa) in women, P < 0.01]. Another study conducted in 
Romania demonstrated that the mean values of  TE in 144 
normal subjects were 4.8 ± 1.3 kPa (range, 2.3-8.8 kPa) 
and that the normal LS values were significantly different 
between genders[16]. Colombo et al[17] also assessed the LS 
values of  327 voluntary blood donors and found that the 
mean LS value was 4.9 kPa (95% CI: 4.6-5.1 kPa) and the 
normal LS values showed no significant differences be-
tween genders. However, Colombo et al[18] in their follow-
up study that enrolled more than 1000 healthy blood 
donors reported that the normal LS value was 4.4 kPa (95th 
percentile, 6.7 kPa) and that the male gender presents with 
increased LS values.
All the aforementioned studies were conducted in 
Europe. However, normal LS values in the Asian popu-
lation are now available. Fung et al[19] reported a mean LS 
value in 28 healthy living-related liver donors of  4.6 kPa 
(range, 2.0-7.1 kPa), and all subjects had LS values of  
< 7.2 kPa, which indicated that they had no significant 
fibrosis. We have previously reported that the normal 
range of  LS values was 3.9-5.3 kPa, which was calculated 
from 69 strictly selected living liver and kidney donors[14].
Table 1 indicates the results of  all studies on normal 
LS values. The upper normal range of  LS values was con-
sistently lower than the range generally used for identifying 
significant liver disease (7-8 kPa) in the majority of  previ-
ous studies[20-22]. These data demonstrated that TE can 
perform reliably in identifying high-risk subpopulations 
without an overlap between the normal and abnormal 
ranges of  LS values. Interestingly, the mean LS values in 
Asian studies appear lower in comparison with European 
studies, and the effects of  gender on the performance of  
TE are variable among studies. The discrepancy cannot be 
fully explained, because the complete histological data of  
the normal subjects were largely unavailable except a small 
Table 1  Normal liver stiffness values of transient elastography
Asian study European study
Kim et al [14] Fung et al [19] Corpechot et al [15] Roulot et al [13] Sirli et al [16] Colombo et al [17] Colombo et al [18] 
Type Full article Full article Letter Full article Full article Abstract Abstract
No. of subjects 69 28 71 429 144 327 746
Population Liver and 
kidney donors
Liver donors Healthy volunteers Medical check-up Healthy 
volunteers
Blood donors Blood donors
Liver stiffness (kPa) 4.6 (mean) 4.6 (median) 4.8 (median) 5.5 (mean) 4.8 (mean) 4.9 (mean) 4.4 (median)
95th percentile (kPa)        4.7 - -        8.6 -        7.8        6.7
BMI (kg/m2) 22.6 (mean) - 22.5 (median) 25.8 (mean) - - -
Effects on TE
   Age No - No No No No No
   Gender M = F - M > F M > F M > F M = F M > F
   High BMI No - No Increased TE values No Increased TE values No
   Metabolic syndrome - - - Increased TE values - - -
   Fatty liver - - - - - Increased TE values Increased TE values
BMI: Body mass index; TE: Transient elastography.
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number of  liver donors in the studies by our group[14] and 
Fung et al[19]. Lower mean BMI, younger age, and lower 
prevalence of  metabolic syndrome in the Asian studies 
can explain, at least in part, the lower mean LS values 
observed. Another reasons are that other confounders of  
TE performance, such as high alanine aminotransferase 
(ALT) levels and fatty liver, were not sufficiently exclud-
ed[17,18] and that the hepatic imaging studies and/or car-
diologic evaluation were not fully completed in European 
studies[13,16]. These reasons may have increased the normal 
range of  LS values in the European studies.
More carefully designed studies with a large num-
ber of  subjects are thus still required to fully assess the 
normal LS values for both Western and Asian popula-
tions. However, it should be remembered that the actual 
normal range of  LS values cannot be precisely defined 
without a definition of  a “normal liver”, sufficient histo-
logical evaluation of  normal subjects, and further strati-
fied analysis with lifestyle factors between genders (such 
as alcohol consumption). If  these issues are resolved, we 
can identify the true normal LS value and use this as a 
reference for future studies.
INFLUENCE OF BMI ON THE 
PERFORMANCE OF TE IN THE ASIAN 
POPULATION 
Previous work has demonstrated that BMI can affect the 
performance of  TE. This can be explained in 2 ways. 
First, BMI influences the failure rate of  TE, and second, 
BMI acts to increase LS values. Although previous stud-
ies have reported that the success rate of  TE decreases in 
subjects displaying higher BMI[13,23], TE failure may not be 
significant, because these patients were largely excluded 
from the analysis. However, in another point of  view, this 
effect of  high BMI on TE failure can be a significant pit-
fall of  TE, as the majority of  patients with high BMI have 
an increased chance of  suffering from fatty liver and, if  
TE examination fails, they miss the opportunity to receive 
rapid and non-invasive methods to exclude significant 
fibrosis. From the knowledge of  the varying failure rates 
between Asian and European study populations, we can 
discern the possible influence of  BMI on TE failure rate 
according to the study population. 
Table 2 summarizes the failure rates of  previous 
studies conducted in Asian and European populations. 
Overall, TE failure rates and BMI both appear to be 
lower in Asian compared to European studies, indicating 
that the lower BMI found in Asian populations is pos-
sibly associated with a lower TE failure rate.
In spite of  debate, several European studies have 
reported that a high BMI (which might cause hepatic ste-
atosis) could potentially increase LS values[13,17], although 
research to date has not determined whether steatosis 
itself  increases LS value in patients with chronic viral 
hepatitis[28-30]. For the Asian population, the effects of  
high BMI on TE performance have not been fully vali-
dated, because most Asian studies on TE lack sufficient 
numbers of  patients with high BMI (> 30 kg/m2). In our 
previous study, BMI did not influence LS values, although 
our study population was younger and showed lower BMI 
values than European studies[14]. This potential effect of  
high BMI on TE performance should therefore be further 
investigated for the Asian population.
INFLUENCE OF METABOLIC SYNDROME 
ON THE PERFORMANCE OF TE IN THE 
ASIAN POPULATION
Recently, the effects of  metabolic syndrome (MS) on TE 
have been examined in a French study[13]. Here, BMI > 
30 kg/m2 was more frequent among subjects with MS than 
among normal subjects (49.1% vs 8.9%, respectively, P < 
0.001). The mean LS value was higher in subjects with MS 
compared to controls (6.51 ± 1.64 kPa vs 5.33 ± 1.51 kPa, 
P < 0.001). In a multivariate analysis, LS values were still 
significantly different between subjects with and without 
MS, irrespective of  BMI and other variables. Because MS 
Table 2  Failure rate of transient elastography measurement
Asian study European study
Kim et al [14] Chan et al [24] Masuzaki et al [25] Wong et al [26] Ziol et al [2] Marcellin et al [10] Maimone et al [27]
Etiology HBV HBV HCV HBV HCV HBV HBV
Total patients (n) 74 1136 876 487 327 202 230
Excluded patients (n)   5     30   10   34   76   29   10
Excluded patients due to TE failure (n)   1     30   10   17   23   14   10
TE failure rate (%)      1.4          2.6        1.1        3.5     7        6.9        4.3
Enrolled patients (n) 69 1106 866 453 251 173 220
   Age (yr) 38.9 (mean) 47 (mean)   66.2 (mean)   37 (median)   47.5 (mean)   40.1 (mean) 45.2 (mean)
   Male, n (%) 35 (50.7) - 398 (46.0)  270 (60.0) 155 (61.8) 115 (66.5) 99 (45.0)
   BMI (kg/m2) 22.6 (mean) -   22.5 (mean) 22.4 (median)   23.9 (mean)   24.5 (mean) -
Failure criteria
   Success rate < 60% < 60% < 60% < 60% < 60% < 50% < 60%
   The number of VMs       < 10 VMs       < 10 VMs     < 8 VMs       < 10 VMs       < 10 VMs     < 7 VMs       < 10 VMs
HBV: Hepatitis B virus; HCV: Hepatitis C virus; TE: Transient elastography; BMI: Body mass index; VM: Valid measurement.
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has been demonstrated to increase LS values significantly, 
and hepatic steatosis which can result in histological 
progression to cirrhosis and hepatocellular carcinoma is 
strongly associated with MS[31-33], a potential role of  TE in 
detecting MS was proposed. However, 88% of  the sub-
jects with MS had LS values within the defined normal 
range. This result indicated that not only could TE not 
precisely perform in the diagnosis of  MS, but also that he-
patic steatosis differentially affected by MS may have influ-
enced LS values differently for different individuals. One 
drawback of  the study[13] was a lack of  ultrasonographic 
evaluation of  hepatic steatosis. It is thus unclear whether 
the increased LS values in the subjects with MS were de-
pendent on MS itself  or on hepatic steatosis associated 
with MS. Other studies in Italy[17,18] attempted to overcome 
this drawback by including ultrasonographic evaluation of  
the healthy blood donors and concluded that the severity 
of  hepatic steatosis was independently related to LS values.
The association between MS or hepatic steatosis and 
LS values was investigated primarily in healthy subjects, 
because the effects of  MS or hepatic steatosis on TE can 
be attenuated if  the study population presented with back-
ground fibrotic liver (the most significant factor for high 
LS values). Therefore, it is difficult to identify the main 
factors that increase LS values among MS, hepatic steato-
sis, associated steatofibrosis, and background fibrosis, if  
the study enrolls patients already presenting with CLD.
As mentioned above, only one published European 
study reporting the effects of  MS on TE in healthy indi-
viduals is currently available. Furthermore, no available 
European and Asian data address the effects of  MS on 
TE performance in patients with chronic viral hepatitis. 
Considering the different clinicopathological course of  
hepatic steatosis in patients with CHC and CHB and the 
varied distribution of  body fat according to race, further 
studies on the effects of  MS and hepatic steatosis should 
be performed with the Asian populations.
INFLUENCE OF ALT ON THE 
PERFORMANCE OF TE IN THE ASIAN 
POPULATION WITH CHB 
The most important confounding factor of  TE is serum 
ALT levels. Hepatic inflammation, as reflected by higher 
ALT levels, tends to increase LS values[11,20,34]. Even minor 
changes in ALT levels have been shown to influence LS 
values[35]. Because HBV, unlike HCV, frequently exhibits 
acute ALT flares[36,37], the interpretation of  LS values be-
comes increasingly difficult in the setting of  CHB when 
major fluctuations of  necrosis and inflammatory activity 
occur[24,38]. It thus becomes more relevant to consider ALT 
levels when examining TE in the Asian population with 
CHB.
Considering the significant effects of  high ALT levels, 
several Asian studies with CHB patients attempted to es-
tablish varying cutoff  LS values according to ALT levels. 
Chan et al[11] proposed ALT-based algorithms when inter-
preting LS results, and established different optimal cutoff  
values according to ALT levels (one group with normal 
ALT vs the other group with ALT > upper limit of  normal 
(ULN) and ≤ 5 × ULN). In our previous study, we also 
stratified the study population according to ALT levels 
and calculated the optimal cutoff  values for each group[34]. 
For patients with normal ALT levels, 6.0, 7.5 and 10.1 kPa 
were selected as the optimal cutoff  values for ≥ F2, ≥ 
F3, and F4, respectively, whereas 8.9, 11.0, and 15.5 kPa 
were selected in those with ALT > ULN and ≤ 2 × 
ULN. Considering this unreliability of  TE performance 
in patients with high ALT levels, more recent studies be-
gan to exclude patients displaying ALT > 5 × ULN for 
analysis[24]. In addition, the optimal time interval for TE 
to recover its reliability in patients who experience acute 
exacerbation of  CHB was recently reported[38].
Although it seems reasonable to use different cutoff  
values according to ALT levels, large-scale validation of  
these LS values has not been performed for Asian pa-
tients with CHB. Furthermore, some issues still remain 
unresolved, such as how we stratify patients with CHB 
according to ALT levels to establish the cutoff  values, and 
who should be excluded for TE examination because of  
unreliability of  TE among patients with high ALT levels.
DIAGNOSTIC PERFORMANCE OF TE IN 
THE ASIAN POPULATION WITH CHB
Few studies have investigated the performance of  TE in 
the Asian population with CHB[4,11,39-43]. The characteris-
tics of  studies and the identified performance of  TE to 
predict significant fibrosis and cirrhosis are summarized 
in Tables 3 and 4 (Marcellin et al[10] is listed for compari-
son with other Asian studies). The listed Asian studies 
were selected if  they evaluated TE in Asian populations 
with CHB, they used LB as a reference standard, and 
they assessed the diagnostic accuracy of  TE [using area 
under the receiver operating characteristic curve (AU-
ROC)] for F ≥ 2 or F = 4 fibrosis stage and/or diag-
nostic indexes (sensitivity, specificity, positive predictive 
value, or negative predictive value based on some cutoff  
LS values). Most Asian studies were conducted in Korea 
and China (Hong Kong) and some studies were available 
in abstract form from Korea, Singapore, and Thailand.
The AUROCs for predicting F ≥ 2 fibrosis and F 
= 4 fibrosis stage in patients with CHC were reported 
as 0.79-0.83 and 0.97-0.95, respectively in the studies by 
Ziol et al[2] and Castera et al[44]. However, the AUROCs in 
Asian studies seems to be lower than those reported in 
European studies (0.76-0.88 for F ≥ 2 and 0.80-0.93 for 
F4, Table 4), although TE diagnosed cirrhosis more ac-
curately than significant fibrosis in Asian studies.
Overall, TE is accepted as a promising and accurate 
tool for the early detection of  cirrhosis irrespective of  
the etiology of  CLD, although the optimal cutoff  values 
remain debatable. The range of  the optimal cutoff  values 
for diagnosing HBV-related cirrhosis in the Asian popu-
lation were between 9.0 and 10.1 kPa based on the full-
length articles[4,11,39] (Table 4) and the range for cirrhosis 
was less than 11.0 kPa, which is consistently lower than in 
Kim SU et al . Transient elastography in chronic hepatitis B
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patients with CHC[45,46]. These findings can be explained 
in several ways. The histopathological characteristics of  
CHC (including portal lymphoid follicles, bile duct dam-
age, lobular activity, and steatosis) may contribute to the 
variations in cutoff  values compared with those in pa-
tients with CHB[47]. Another explanation is that the total 
fibrotic material in CHB may be lower than that in CHC, 
because CHB tends to make the liver macronodular and 
heterogeneous[48]. Other researchers have proposed that 
the different types and extent of  liver inflammatory infil-
trate within the liver may account for the different cutoff  
LS values between CHB and CHC[20].
The performance of  TE in prediction of  cirrhosis is 
acceptable for the Asian population with CHB, but in-
creased performance in prediction of  significant fibrosis 
and subsequent precise staging, particularly for patients 
with CHB who are candidates for antiviral treatment, is 
needed and should be pursued through future studies. 
This is particularly important, because the decision to start 
antiviral treatment and the type of  antiviral agents to be 
used may be affected by fibrosis stage. 
CONCLUSION
Because of  limitations of  LB, prohibiting its routine use 
for the evaluation of  liver fibrosis in patients with CHB, 
interest in the use of  noninvasive TE has increased. Ide-
ally, TE can be used to screen the general population to 
detect high-risk patients with potential liver disease, to 
identify patients with significant fibrosis who could ben-
efit from the initiation of  antiviral treatment, to select 
patients with cirrhosis who are at a high risk of  develop-
ing HCC[25], and to identify patients with cirrhosis and 
portal hypertension. To date, although numerous Euro-
pean studies have demonstrated that this is possible, data 
on TE for the Asian population are scarce.
We are now fully armed with nuggets of  knowledge 
that the etiologies of  CLD, BMI, MS, cardiac function, 
cholestasis, hepatic steatosis, and ALT levels can influence 
the performance of  TE, and also that several confound-
ers vary between Asian and European populations, for 
example, the etiology of  CLD, major fluctuation in ALT 
levels, and the prevalence of  high BMI and MS. However, 
because almost all information on TE has thus far origi-
nated from European data, for the Asian population with 
CHB, TE is not popular clinically. Therefore, further stud-
ies tailored to the Asian population with CHB will restore 
the confidence of  Asian clinicians to utilize TE.
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